Carlsmed (NASDAQ:CARL – Free Report) had its price target hoisted by Needham & Company LLC from $17.00 to $22.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. BTIG Research raised their target price on shares of Carlsmed from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Truist Financial lifted their price target on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research report on Wednesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.
Check Out Our Latest Analysis on CARL
Carlsmed Price Performance
Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The firm had revenue of $21.55 million for the quarter. As a group, analysts expect that Carlsmed will post -1.53 EPS for the current fiscal year.
Institutional Trading of Carlsmed
Several institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG bought a new position in Carlsmed during the 2nd quarter worth $106,000. Bank of America Corp DE bought a new stake in shares of Carlsmed in the second quarter valued at about $108,000. Alpine Woods Capital Investors LLC bought a new stake in shares of Carlsmed in the second quarter valued at about $161,000. Bank of New York Mellon Corp acquired a new position in shares of Carlsmed in the second quarter valued at about $181,000. Finally, Zevenbergen Capital Investments LLC grew its stake in shares of Carlsmed by 50.4% in the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after acquiring an additional 6,000 shares in the last quarter.
Carlsmed Company Profile
Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.
See Also
- Five stocks we like better than Carlsmed
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.
